Refine by
Cytology Articles & Analysis: This-Year
10 articles found
Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for its cutting-edge preclinical alfaCAR-T solutions. ...
Alfa Cytology has revealed new FAP-targeted therapeutics development services that aim to develop precise and effective cancer treatments. Alfa Cytology has introduced its groundbreaking initiative which targets fibroblast activation protein(FAP) for cancer therapies. ...
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. ...
In recent years, the fight against cancer has seen significant advances, particularly with the emergence of targeted therapy. Among the most promising strategies in this domain is the development of radioactive drug conjugates(RDCs). These innovative therapeutic agents combine the targeting capabilities of antibodies with the cytotoxic effects of radioactive isotopes, providing a powerful ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. ...
In the ever-evolving landscape of cancer research, two intriguing concepts have emerged that are reshaping how scientists approach treatment: synthetic lethality and parthanatos. Both concepts encapsulate the complexity of cellular processes and open new avenues for targeted therapies. What is Synthetic Lethality? Synthetic lethality occurs when the simultaneous disruption of two genes ...
Alfa Cytology has launched ovarian cancer therapy development services. Alfa Cytology, a prominent services provider in oncology, has launched its cutting-edge ovarian cancer therapy development services. ...
Alfa Cytology unveils advanced cancer immunotherapy development services. Alfa Cytology, a renowned services supplier in oncology, has recently introduced its groundbreaking cancer immunotherapy development services. ...
Alfa Cytology introduces comprehensive small molecule PARPi development services for combating various diseases. Alfa Cytology, a developer of oncology innovation, has announced its latest venture small molecule Poly(ADP-ribose) polymerase inhibitor development services. ...
Leukemia, a malignant disorder of the blood and bone marrow, poses significant challenges to both patients and healthcare providers. Traditional treatments, including chemotherapy and radiation, while effective for some, often come with severe side effects and varied success rates. Enter immunotherapy - a groundbreaking approach that is not only redefining leukemia treatment but also offering ...